Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Change in Accured Expenses (2019 - 2025)

Historic Change in Accured Expenses for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $1.8 million.

  • Eton Pharmaceuticals' Change in Accured Expenses rose 21114.98% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 22245.4%. This contributed to the annual value of $1.5 million for FY2024, which is 4008.88% down from last year.
  • According to the latest figures from Q3 2025, Eton Pharmaceuticals' Change in Accured Expenses is $1.8 million, which was up 21114.98% from $172000.0 recorded in Q2 2025.
  • Eton Pharmaceuticals' Change in Accured Expenses' 5-year high stood at $2.0 million during Q4 2024, with a 5-year trough of -$1.6 million in Q1 2024.
  • In the last 5 years, Eton Pharmaceuticals' Change in Accured Expenses had a median value of $368000.0 in 2021 and averaged $321631.6.
  • Per our database at Business Quant, Eton Pharmaceuticals' Change in Accured Expenses skyrocketed by 423000.0% in 2023 and then crashed by 23228.41% in 2024.
  • Eton Pharmaceuticals' Change in Accured Expenses (Quarter) stood at $120000.0 in 2021, then tumbled by 153.33% to -$64000.0 in 2022, then skyrocketed by 2246.88% to $1.4 million in 2023, then soared by 48.69% to $2.0 million in 2024, then dropped by 12.58% to $1.8 million in 2025.
  • Its Change in Accured Expenses stands at $1.8 million for Q3 2025, versus $172000.0 for Q2 2025 and -$1.4 million for Q1 2025.